Page 49 - Read Online

Page 16 of 19 Matrone et al. J Cancer Metastasis Treat 2021;7:23 https://dx.doi.org/10.20517/2394-4722.2021.47

29. Gharib H, Mcconahey WM, Tiegs RD, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65
patients treated during 1946 through 1970. Mayo Clinic Proceedings 1992;67:934-40. DOI PubMed
30. Matrone A, Gambale C, Prete A, et al. Impact of advanced age on the clinical presentation and outcome of sporadic medullary
thyroid carcinoma. Cancers (Basel) 2020;13:94. DOI PubMed PMC
31. Kebebew E, Ituarte PHG, Siperstein AE, Duh Q, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment,
prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-48. DOI PubMed
32. Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw 2010;8:549-56. DOI
PubMed
33. Romei C, Mariotti S, Fugazzola L, et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network
analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol 2010;163:301-8. DOI PubMed
34. Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab
2008;22:941-53. DOI PubMed
35. Wells SA Jr, Asa SL, Dralle H, et al. Revised american thyroid association guidelines for the management of medullary thyroid
carcinoma. Thyroid 2015;25:567-610. DOI PubMed PMC
36. Valerio L, Pieruzzi L, Giani C, et al. Targeted therapy in thyroid cancer: state of the art. Clin Oncol (R Coll Radiol) 2017;29:316-24.
DOI PubMed
37. Viola D, Elisei R. Management of medullary thyroid cancer. Endocrinol Metab Clin North Am 2019;48:285-301. DOI PubMed
38. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25. DOI PubMed
39. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117-34. DOI PubMed PMC
40. Bible KC, Ryder M. Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol 2016;13:403-
16. DOI PubMed
41. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid
leukemia. N Engl J Med 2001;344:1031-7. DOI PubMed
42. Tacconi EMC, Tuthill M, Protheroe A. Review of adjuvant therapies in renal cell carcinoma: evidence to date. Onco Targets Ther
2020;13:12301-16. DOI PubMed PMC
43. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. DOI PubMed
44. Matrone A, Valerio L, Pieruzzi L, et al. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory
thyroid tumors: from the clinical trials to the real life. Best Pract Res Clin Endocrinol Metab 2017;31:319-34. DOI PubMed
45. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated
thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28. DOI PubMed PMC
46. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med
2015;372:621-30. DOI PubMed
47. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010;13:1-14.
DOI PubMed PMC
48. Posner I, Engel M, Gazit A, Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth
factor receptor and analysis by a new computer program. Mol Pharmacol 1994;45:673-83. PubMed
49. Viola D, Valerio L, Molinaro E, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr
Relat Cancer 2016;23:R185-205. DOI PubMed
50. Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016;375:1054-67. DOI PubMed PMC
51. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple
endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-41. DOI PubMed
52. Krampitz GW, Norton JA. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial
medullary thyroid carcinoma. Cancer 2014;120:1920-31. DOI PubMed
53. Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an
update. J Clin Endocrinol Metab 2013;98:3149-64. DOI PubMed PMC
54. Raue F, Bruckner T, Frank-Raue K. Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma: 40 years of
experience at one center. J Clin Endocrinol Metab 2019;104:4264-72. DOI PubMed
55. Romei C, Casella F, Tacito A, et al. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad
outcome of cases with double RET mutations. J Med Genet 2016;53:729-34. DOI PubMed
56. Agrawal N, Jiao Y, Sausen M, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive
oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013;98:E364-9. DOI PubMed PMC
57. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid
carcinoma. J Clin Endocrinol Metab 2007;92:3466-9. DOI PubMed
58. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results
from a phase II study. J Clin Oncol 2008;26:4708-13. DOI PubMed PMC
59. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or
symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801. DOI PubMed
60. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol
2010;28:2323-30. DOI PubMed PMC
61. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated
thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res